Nuvation Bio Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was License at $38.2 million, 61% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
202
|
63
|
8
|
—
|
—
|
—
|
| License |
117
+557.1%
share 57.9%
|
38
share 60.8%
|
—
|
—
|
—
|
—
|
| Product |
85
share 42.1%
|
25
share 39.2%
|
—
|
—
|
—
|
—
|
| Research And Development Service Revenue |
—
|
—
|
6
share 73.5%
|
—
|
—
|
—
|
| License Revenue |
—
|
—
|
2
share 26.5%
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NUVB (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1811063
- Former names
- Panacea Acquisition Corp (until Feb 11, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.